Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong.
C-MER International Eye Care Group, Hong Kong.
Asia Pac J Ophthalmol (Phila). 2021 Nov 24;10(6):521-529. doi: 10.1097/APO.0000000000000453.
The coronavirus disease 2019 (COVID-19) came under the attention of the international medical community when China first notified the World Health Organization of a pneumonia outbreak of then-unknown etiology in Wuhan in December 2019. Since then, COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has appalled the world by spreading at a pandemic speed. Although ophthalmologists do not directly engage in the clinical care of COVID-19 patients, the ophthalmology community has become aware of the close ties between its practice and the pandemic. Not only are ophthalmologists at heightened risk of SARS-CoV-2 exposure due to their physical proximity with patients in routine ophthalmic examinations, but SARS-CoV-2 possesses ocular tropism resulting in ocular complications beyond the respiratory tract after viral exposure. Furthermore, patients could potentially suffer from adverse ocular effects in the therapeutic process. This review summarized the latest literature to cover the ophthalmic manifestations, effects of treatments, and vaccinations on the eye to aid the frontline clinicians in providing effective ophthalmic care to COVID-19 patients as the pandemic continues to evolve.
当中国于 2019 年 12 月首次向世界卫生组织通报武汉不明原因肺炎疫情时,2019 年冠状病毒病(COVID-19)引起了国际医学界的关注。此后,由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的 COVID-19 以大流行的速度迅速蔓延,震惊了世界。尽管眼科医生并不直接参与 COVID-19 患者的临床护理,但眼科界已经意识到其实践与大流行之间的密切联系。由于眼科医生在常规眼科检查中与患者身体接触密切,因此他们面临着更高的 SARS-CoV-2 暴露风险,而且 SARS-CoV-2 具有眼向性,导致病毒暴露后除呼吸道外还出现眼部并发症。此外,患者在治疗过程中可能会出现眼部不良反应。本综述总结了最新的文献,以涵盖眼科表现、治疗效果和疫苗对眼睛的影响,以帮助一线临床医生在大流行不断发展的情况下为 COVID-19 患者提供有效的眼科护理。